Uterine leiomyosarcoma is a rare form of sarcoma with limited treatment options and a high potential for distant recurrence. At the time of diagnosis, swift action should be taken to initiate treatment. Options for treatment include surgical debulking and disease staging, radiation therapy, and/or chemotherapy. The purpose of this article is to review the disease epidemiology, presentation at diagnosis, surgical staging, and prognosis. Treatment options and the role of targeted therapies are discussed in addition to the various nursing implications associated with management of the disease.

Uterine sarcomas consist of a group of aggressive and rare cancers that originate from mesenchymal tissue (Lin & Slomovitz, 2008). Mesenchymal tissue is embryonic in origin and is part of the embryonic mesoderm from which blood vessels, lymphatic vessels, and connective tissue arise. Tumors from mesenchymal cells make up about 4% of uterine cancers and uterine leiomyosarcoma (LMS) accounts for about a quarter of that 4% (Bernstein-Molho, Grisaro, Soyfer, Safra, & Merimsky, 2010). Risk factors for the development of uterine LMS are not well known; however, the annual incidence is about 0.64 per 100,000 women (Zivanovic et al., 2009).

Risk factors for the development of uterine LMS are not fully understood; however, some possible risk factors include long-term use of tamoxifen, a history of pelvic irradiation, and being of African American heritage (Lin & Slomovitz, 2008). In addition, an increased incidence is noted in women aged 40–60 years (Lin & Slomovitz, 2008).

Although rare, uterine LMS may develop within a leiomyoma (Berek & Hacker, 2005). Leiomyomas are noncancerous, smooth muscle tumors that develop within the female genital tract and occur in about 40% of women older than age 40 (Al-Nafussi, 2004). Unlike uterine LMS, leiomyomas are relatively easy to diagnose pathologically and clinically (Watanabe & Suzuki, 2006). In some cases, uterine leiomyomas may transform into LMS. Yanai et al. (2010) performed a retrospective study and found 6 of 10 cases of uterine LMS arising from leiomyomas of the broad ligament and uterus. The malignant transformation of uterine leiomyomas is more likely to occur in women ranging in age from 40–73 years. However, the prognosis for patients diagnosed with uterine LMS arising from preexisting leiomyomas is better than for patients diagnosed with primary uterine LMS (Yanai et al., 2010).

**Uterine Leiomyosarcoma**

**Presentation**

The typical symptoms of uterine LMS include pain, vaginal bleeding, and the presence of a pelvic mass (Giuntoli & Bristow, 2004). Patients with uterine LMS may present with abnormal uterine bleeding, abdominal pain, and pelvic mass. Other symptoms may include an increase in bleeding, pelvic pressure, and a pelvic mass. The diagnosis of uterine LMS is typically made using imaging studies such as computed tomography (CT) scans or magnetic resonance imaging (MRI) scans, and biopsy of the lesion to confirm the diagnosis. Treatment options for uterine LMS include surgical debulking, chemotherapy, and radiation therapy. The choice of treatment depends on the stage of the disease, the size of the tumor, and the overall health of the patient. The prognosis for patients with uterine LMS is generally poor, with a 5-year survival rate of about 30% (Al-Nafussi, 2004).